Arcus Biosciences (RCUS) Income towards Parent Company: 2017-2025
Historic Income towards Parent Company for Arcus Biosciences (RCUS) over the last 7 years, with Sep 2025 value amounting to -$135.0 million.
- Arcus Biosciences' Income towards Parent Company fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
- According to the latest figures from Q3 2025, Arcus Biosciences' Income towards Parent Company is -$135.0 million, which was down 20.54% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' 5-year Income towards Parent Company high stood at $279.5 million for Q4 2021, and its period low was -$135.0 million during Q3 2025.
- Over the past 3 years, Arcus Biosciences' median Income towards Parent Company value was -$86.5 million (recorded in 2023), while the average stood at -$83.7 million.
- Data for Arcus Biosciences' Income towards Parent Company shows a peak YoY increase of 637.62% (in 2021) and a maximum YoY decrease of 4,379.64% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Arcus Biosciences' Income towards Parent Company stood at $279.5 million in 2021, then crashed by 123.97% to -$67.0 million in 2022, then decreased by 20.90% to -$81.0 million in 2023, then dropped by 16.05% to -$94.0 million in 2024, then plummeted by 46.74% to -$135.0 million in 2025.
- Its Income towards Parent Company was -$135.0 million in Q3 2025, compared to -$112.0 million in Q1 2025 and -$94.0 million in Q4 2024.